Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?

Skip to the main content

Liječnički vjesnik, Vol. 145 No. Supp 2, 2023.

Meeting abstract

https://doi.org/10.26800/LV-145-supl2-CR63

Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?

Džana Bjelić ; School of Medicine, University of Zagreb, Zagreb, Croatia
Sara Bognar
Jelena Benčić
Manuela Bajan
Natalija Dedić Plavetić

Full text: english pdf 294 Kb

page 78-78

downloads: 245

APA 6th Edition

Bjelić, Dž., Bognar, S., Benčić, J., Bajan, M. & Dedić Plavetić, N. (2023). Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?. Liječnički vjesnik, 145 (Supp 2), 78-78. https://doi.org/10.26800/LV-145-supl2-CR63

MLA 8th Edition

Bjelić, Džana, et al. "Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?." Liječnički vjesnik, vol. 145, no. Supp 2, 2023, pp. 78-78. https://doi.org/10.26800/LV-145-supl2-CR63. Accessed 25 Nov. 2024.

Chicago 17th Edition

Bjelić, Džana, Sara Bognar, Jelena Benčić, Manuela Bajan and Natalija Dedić Plavetić. "Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?." Liječnički vjesnik 145, no. Supp 2 (2023): 78-78. https://doi.org/10.26800/LV-145-supl2-CR63

Harvard

Bjelić, Dž., et al. (2023). 'Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?', Liječnički vjesnik, 145(Supp 2), pp. 78-78. https://doi.org/10.26800/LV-145-supl2-CR63

Vancouver

Bjelić Dž, Bognar S, Benčić J, Bajan M, Dedić Plavetić N. Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?. Liječnički vjesnik [Internet]. 2023 [cited 2024 November 25];145(Supp 2):78-78. https://doi.org/10.26800/LV-145-supl2-CR63

IEEE

Dž. Bjelić, S. Bognar, J. Benčić, M. Bajan and N. Dedić Plavetić, "Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?", Liječnički vjesnik, vol.145, no. Supp 2, pp. 78-78, 2023. [Online]. https://doi.org/10.26800/LV-145-supl2-CR63

Abstract

Breast cancer that overexpresses the human epidermal growth factor receptor 2 (HER2) is considered to be HER2-positive. The novel HER2-
directed antibody drug conjugate, trastuzumab deruxtecan (T-DXd), is formed by covalently joining the monoclonal antibody trastuzumab with the topoisomerase I inhibitor deruxtecan. It exhibits significant anti-tumor activity in previously overtreated patients.

Keywords

breast cancer; metastasis; pneumonitis; trastuzumab deruxtecan

Hrčak ID:

303988

URI

https://hrcak.srce.hr/303988

Publication date:

23.4.2023.

Visits: 599 *